Search tips
Search criteria 


Logo of pubhealthrepPublic Health Reports
Public Health Rep. 1998 June; 113(Suppl 1): 116–128.
PMCID: PMC1307734

Facilitating treatment entry among out-of-treatment injection drug users.


OBJECTIVE: High risk injection practices are common among injecting drug users (IDUs), even following intervention efforts. Moreover, relapse to risk behaviors has been reported among those who initiate risk reduction. Substance abuse treatment offers the potential to reduce or eliminate injecting risk behaviors through drug cessation. We report on the effectiveness of two intervention strategies in facilitating treatment entry among out-of-treatment IDUs: motivational interviewing (MI), and intervention developed to help individuals resolve their ambivalence about behavior change, and free treatment for 90 days. These conditions were compared with an intervention focusing on a hierarchy of safer injecting practice, referred to here as risk reduction (RR), and no free treatment. METHODS: Nearly 200 out-of-treatment IDUs were randomly assigned to one of four experimental conditions: MI/free treatment, MI/no free treatment, RR/free treatment, and RR/no free treatment. Regardless of assignment, we assisted anyone desiring treatment by calling to schedule the appointment, providing transportation, and waiving the intake fee. RESULTS: Overall, 42% of study participants entered treatment. No significant differences were found between MI and RR; however, 52% of those assigned free treatment entered compare with 32% for those who had to pay. Other predictors of treatment entry included prior treatment experiences, perceived chance of contracting acquired immunodeficiency syndrome (AIDS) greater than 50%, "determination" stage of change, greater frequency of heroin injecting, and fewer drug-using friends. CONCLUSIONS: These findings support the importance of removing barriers to treatment entry.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (2.8M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Barré-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, Dauguet C, Axler-Blin C, Vézinet-Brun F, Rouzioux C, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science. 1983 May 20;220(4599):868–871. [PubMed]
  • Friedland GH, Klein RS. Transmission of the human immunodeficiency virus. N Engl J Med. 1987 Oct 29;317(18):1125–1135. [PubMed]
  • Holmberg SD. The estimated prevalence and incidence of HIV in 96 large US metropolitan areas. Am J Public Health. 1996 May;86(5):642–654. [PubMed]
  • Power R, Hartnoll R, Daviaud E. Drug injecting, AIDS, and risk behaviour: potential for change and intervention strategies. Br J Addict. 1988 Jun;83(6):649–654. [PubMed]
  • Bortolotti F, Stivanello A, Dall'Armi A, Rinaldi R, La Grasta F. AIDS information campaign has significantly reduced risk factors for HIV infection in Italian drug abusers. J Acquir Immune Defic Syndr. 1988;1(4):412–413. [PubMed]
  • Colón HM, Robles RR, Freeman D, Matos T. Effects of a HIV risk reduction education program among injection drug users in Puerto Rico. P R Health Sci J. 1993 Apr;12(1):27–34. [PubMed]
  • Watters JK, Downing M, Case P, Lorvick J, Cheng YT, Fergusson B. AIDS prevention for intravenous drug users in the community: street-based education and risk behavior. Am J Community Psychol. 1990 Aug;18(4):587–596. [PubMed]
  • Ball JC, Lange WR, Myers CP, Friedman SR. Reducing the risk of AIDS through methadone maintenance treatment. J Health Soc Behav. 1988 Sep;29(3):214–226. [PubMed]
  • Hartgers C, van den Hoek A, Krijnen P, Coutinho RA. HIV prevalence and risk behavior among injecting drug users who participate in "low-threshold" methadone programs in Amsterdam. Am J Public Health. 1992 Apr;82(4):547–551. [PubMed]
  • Watters JK, Estilo MJ, Clark GL, Lorvick J. Syringe and needle exchange as HIV/AIDS prevention for injection drug users. JAMA. 1994 Jan 12;271(2):115–120. [PubMed]
  • Des Jarlais DC, Marmor M, Paone D, Titus S, Shi Q, Perlis T, Jose B, Friedman SR. HIV incidence among injecting drug users in New York City syringe-exchange programmes. Lancet. 1996 Oct 12;348(9033):987–991. [PubMed]
  • Calsyn DA, Saxon AJ, Freeman G, Jr, Whittaker S. Ineffectiveness of AIDS education and HIV antibody testing in reducing high-risk behaviors among injection drug users. Am J Public Health. 1992 Apr;82(4):573–575. [PubMed]
  • Casadonte PP, Des Jarlais DC, Friedman SR, Rotrosen JP. Psychological and behavioral impact among intravenous drug users of learning HIV test results. Int J Addict. 1990 Apr;25(4):409–426. [PubMed]
  • Skidmore CA, Robertson JR, Roberts JJ. Changes in HIV risk-taking behaviour in intravenous drug users: a second follow-up. Br J Addict. 1989 Jun;84(6):695–696. [PubMed]
  • Booth R, Koester S, Brewster JT, Weibel WW, Fritz RB. Intravenous drug users and AIDS: risk behaviors. Am J Drug Alcohol Abuse. 1991 Sep;17(3):337–353. [PubMed]
  • Booth RE. Predictors of unsafe needle practices: injection drug users in Denver. J Acquir Immune Defic Syndr. 1994 May;7(5):504–508. [PubMed]
  • Des Jarlais DC, Abdul-Quader A, Tross S. The next problem: maintenance of AIDS risk reduction among intravenous drug users. Int J Addict. 1991 Dec;26(12):1279–1292. [PubMed]
  • Simpson DD. Treatment for drug abuse. Follow-up outcomes and length of time spent. Arch Gen Psychiatry. 1981 Aug;38(8):875–880. [PubMed]
  • McLellan AT, Luborsky L, O'Brien CP, Barr HL, Evans F. Alcohol and drug abuse treatment in three different populations: is there improvement and is it predictable? Am J Drug Alcohol Abuse. 1986;12(1-2):101–120. [PubMed]
  • Ball JC, Lange WR, Myers CP, Friedman SR. Reducing the risk of AIDS through methadone maintenance treatment. J Health Soc Behav. 1988 Sep;29(3):214–226. [PubMed]
  • Longshore D, Hsieh S, Danila B, Anglin MD. Methadone maintenance and needle/syringe sharing. Int J Addict. 1993 Aug;28(10):983–996. [PubMed]
  • Metzger DS, Woody GE, McLellan AT, O'Brien CP, Druley P, Navaline H, DePhilippis D, Stolley P, Abrutyn E. Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up. J Acquir Immune Defic Syndr. 1993 Sep;6(9):1049–1056. [PubMed]
  • Moss AR, Vranizan K, Gorter R, Bacchetti P, Watters J, Osmond D. HIV seroconversion in intravenous drug users in San Francisco, 1985-1990. AIDS. 1994 Feb;8(2):223–231. [PubMed]
  • Williams AB, McNelly EA, Williams AE, D'Aquila RT. Methadone maintenance treatment and HIV type 1 seroconversion among injecting drug users. AIDS Care. 1992;4(1):35–41. [PubMed]
  • Schuster CR. Intravenous drug use and AIDS prevention. Public Health Rep. 1988 May-Jun;103(3):261–266. [PMC free article] [PubMed]
  • Brickner PW, Torres RA, Barnes M, Newman RG, Des Jarlais DC, Whalen DP, Rogers DE. Recommendations for control and prevention of human immunodeficiency virus (HIV) infection in intravenous drug users. Ann Intern Med. 1989 May 15;110(10):833–837. [PubMed]
  • Woody G, O'Hare K, Mintz J, O'Brien C. Rapid intake: a method for increasing retention rate of heroin addicts seeking methadone treatment. Compr Psychiatry. 1975 Mar-Apr;16(2):165–169. [PubMed]
  • Dennis ML, Ingram PW, Burks ME, Rachal JV. Effectiveness of streamlined admissions to methadone treatment: a simplified time-series analysis. J Psychoactive Drugs. 1994 Apr-Jun;26(2):207–216. [PubMed]
  • Festinger DS, Lamb RJ, Kirby KC, Marlowe DB. The accelerated intake: a method for increasing initial attendance to outpatient cocaine treatment. J Appl Behav Anal. 1996 Fall;29(3):387–389. [PMC free article] [PubMed]
  • Sorensen JL, Costantini MF, Wall TL, Gibson DR. Coupons attract high-risk untreated heroin users into detoxification. Drug Alcohol Depend. 1993 Feb;31(3):247–252. [PubMed]
  • Wells EA, Fleming C, Calsyń DA, Jackson TR, Saxon AJ. Users of free treatment slots at a community-based methadone maintenance clinic. J Subst Abuse Treat. 1995 Jan-Feb;12(1):13–18. [PubMed]
  • Jackson JF, Rotkiewicz LG, Quinones MA, Passannante MR. A coupon program--drug treatment and AIDS education. Int J Addict. 1989 Nov;24(11):1035–1051. [PubMed]
  • Bux DA, Iguchi MY, Lidz V, Baxter RC, Platt JJ. Participation in an outreach-based coupon distribution program for free methadone detoxification. Hosp Community Psychiatry. 1993 Nov;44(11):1066–1072. [PubMed]
  • Saunders B, Wilkinson C, Phillips M. The impact of a brief motivational intervention with opiate users attending a methadone programme. Addiction. 1995 Mar;90(3):415–424. [PubMed]
  • Hellinger FJ. The lifetime cost of treating a person with HIV. JAMA. 1993 Jul 28;270(4):474–478. [PubMed]
  • Alterman AI, Kampman K, Boardman CR, Cacciola JS, Rutherford MJ, McKay JR, Maany I. A cocaine-positive baseline urine predicts outpatient treatment attrition and failure to attain initial abstinence. Drug Alcohol Depend. 1997 Jun 6;46(1-2):79–85. [PubMed]
  • Willems JC, Iguchi MY, Lidz V, Bux DA., Jr Change in drug-using networks of injecting drug users during methadone treatment: a pilot study using snowball recruitment and intensive interviews. Subst Use Misuse. 1997 Sep;32(11):1539–1554. [PubMed]

Articles from Public Health Reports are provided here courtesy of SAGE Publications